Results 11 to 20 of about 776,666 (283)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

Biologics: Targets & Therapy, 2013
Katherine Ververis,1 Alison Hiong,1 Tom C Karagiannis,1,* Paul V Licciardi2,*1Epigenomic Medicine, Alfred Medical Research and Education Precinct, 2Allergy and Immune Disorders, Murdoch Childrens Research Institute, Melbourne, VIC, Australia*These ...
Ververis K, Hiong A, Karagiannis TC, Licciardi PV   +3 more
doaj   +2 more sources

HDACiDB: a database for histone deacetylase inhibitors

Drug Design, Development and Therapy, 2015
Kasi Murugan,1 Shanmugasamy Sangeetha,2 Shanmugasamy Ranjitha,2 Antony Vimala,2 Saleh Al-Sohaibani,1 Gopal Rameshkumar21Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia; 2Bioinformatics Laboratory ...
Murugan K, Sangeetha S, Ranjitha S, Vimala A, Al-Sohaibani S, Rameshkumar G   +5 more
doaj   +1 more source

Histone Deacetylase Inhibitors: A Novel Strategy for Neuroprotection and Cardioprotection Following Ischemia/Reperfusion Injury

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Ischemia/reperfusion injury is a complex molecular cascade that causes deleterious cellular damage and organ dysfunction. Stroke, sudden cardiac arrest, and acute myocardial infarction are the most common causes of ischemia/reperfusion injury without ...
Zachary Pickell, Aaron M. Williams, Hasan B. Alam, Cindy H. Hsu   +3 more
doaj   +1 more source

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas

Haematologica, 2018
Histone deacetylase inhibitors are promising agents for various T-cell lymphomas, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and adult T-cell lymphoma/leukemia. CCR4 is an important therapeutic target molecule because mogamulizumab,
Akihiro Kitadate, Sho Ikeda, Fumito Abe, Naoto Takahashi, Norio Shimizu, Kosei Matsue, Hiroyuki Tagawa   +6 more
doaj   +1 more source

Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3 [PDF]

, 2012
The 5-lipoxygenase (5-LO) is the key enzyme in the formation of leukotrienes. We have previously shown that the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) activates 5-LO transcription via recruitment of Sp1, Sp3 and RNA polymerase II to ...
Julia Metzner, Metzner, Julia, Nicole Schnur, Manuel Grez, Grez, Manuel, Katryniok, Careen, Careen Katryniok, Bernd L. Sorg, Dieter Steinhilber, Laura Pufahl, Sorg, Bernd Lothar, Pufahl, Laura, Schnur, Nicole, Steinhilber, Dieter   +13 more
core   +1 more source

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

Haematologica, 2009
Histone deacetylase inhibitors are a class of anti-neoplastic agents that induce growth arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo.
David Ritchie, Richard L. Piekarz, Piers Blombery, Laszlo J. Karai, Stefania Pittaluga, Elaine S. Jaffe, Mark Raffeld, John E. Janik, H. Miles Prince, Susan E. Bates   +9 more
doaj   +1 more source

Induction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2. [PDF]

PLoS ONE, 2013
Neurotrophins and modifiers of chromatin acetylation and deacetylation participate in regulation of transcription during neuronal maturation and maintenance.
Samira Chandwani, Serene Keilani, Maitane Ortiz-Virumbrales, Andrika Morant, Steve Bezdecny, Michelle E Ehrlich   +5 more
doaj   +1 more source

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma [PDF]

, 2008
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone deacetylase (HDAC) inhibitory properties. However, the effects of valproic acid (VPA) are limited and concentrations required for exerting anti ...
P. D. Soldato, L. Hudak, A. Atmaca, Hudak, Lukasz, A. Sparatore, S. A. Wedel, R. A. Blaheta, Jüngel, Eva, Sparatore, Anna, Blaheta, Roman A., Wedel, Steffen Alexander, D. Jonas, S. E. Al Batran, E. Juengel, Jonas, Dietger, Soldato, Piero Del, Batran, Salah-Eddin al-, Atmaca, Akin   +17 more
core   +1 more source

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers

Advanced Biomedical Research, 2019
Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation.
Masumeh Sanaei, Fraidoon Kavoosi
doaj   +1 more source

Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation

Frontiers in Immunology, 2021
Histone deacetylase inhibitors are currently the most studied drugs because of their beneficial effects on inflammatory response. Emerging data from numerous basic studies and clinical trials have shown that histone deacetylase inhibitors can suppress ...
Xiaoxiao Xu, Xiaoxiao Xu, Xiaoxiao Xu, Xiaoxiao Xu, Xiaoqin Li, Xiaoqin Li, Xiaoqin Li, Xiaoqin Li, Yanmin Zhao, Yanmin Zhao, Yanmin Zhao, Yanmin Zhao, He Huang, He Huang, He Huang, He Huang   +15 more
doaj   +1 more source